Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Moderna plans to prioritize new product approvals and oncology investments, as political concerns over Robert F. Kennedy Jr.'s HHS nomination weigh on vaccine stocks.

HSBC upgraded Moderna (MRNA) to Hold from Reduce with a $58 price target Don't Miss our Black Friday Offers:Discover the latest stocks ...

HSBC analyst Yifeng Liu upgraded Moderna (MRNA) to Buy from Hold with a price target of $58, down from $82. The recent share price weakness ...

Shares of vaccine makers such as Moderna (MRNA) and Pfizer (PFE) have plunged on news that president-elect Donald Trump has ...

Shares started out the week mixed in Asia after U.S. stocks fell to their worst loss since Election Day. Japan’s Nikkei 225 index dropped 1% to 38,255.65 as the yen regained some strength against the ...

(Reuters) -Shares in European vaccine makers fell on Friday after U.S. President-elect Donald Trump picked Robert F. Kennedy ...

Monolithic Power Systems, Inc. MPWR lost 24.68% last week as it was hit by an Edgewater Research analyst report that stated ...

Pfizer's stock dropped 4.3 percent while Moderna's fell 3.1 percent and Novavax saw a 2.8 percent dip in its stock Friday ...

Applied Materials tumbles after issuing a disappointing fiscal first-quarter outlook, Palantir is transferring its stock listing to the Nasdaq, and Tesla rises following a decline on worries President ...

The standout company among those yet to report is Nvidia Corp. (NVDA), which is scheduled to announce quarterly results on Wednesday.

The S&P 500 sank 1.1 per cent and was heading for a losing week and its worst day since October. The Dow Jones Industrial ...